Hormone Naive Prostate Cancer clinical trials

Explore recruiting hormone naive prostate cancer clinical trials.

Recruiting hormone naive prostate cancer studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Hormone Naive Prostate Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

EORTC-1532-GUCG: A phase 2 Randomized Open-Label Study of Oral darolutamide (ODM-201) vs. androgen deprivation therapy (ADT) with LHRH agonists or antagonist in Men with Hormone Naive Prostate Cancer.

Italy, Spain, France, Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

Hormone Naive Prostate Cancer trials by city

Hormone Naive Prostate Cancer in Toronto Hormone Naive Prostate Cancer in Vancouver Hormone Naive Prostate Cancer in Montreal Hormone Naive Prostate Cancer in Calgary Hormone Naive Prostate Cancer in Edmonton Hormone Naive Prostate Cancer in Ottawa Hormone Naive Prostate Cancer in Winnipeg Hormone Naive Prostate Cancer in Quebec City Hormone Naive Prostate Cancer in Hamilton Hormone Naive Prostate Cancer in Kitchener Hormone Naive Prostate Cancer in London Hormone Naive Prostate Cancer in Halifax Hormone Naive Prostate Cancer in New York Hormone Naive Prostate Cancer in Los Angeles Hormone Naive Prostate Cancer in Chicago Hormone Naive Prostate Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease